Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Exelixis (DE:EX9)
BERLIN:EX9
Holding DE:EX9?
Track your performance easily
EX9 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€17.85 - €26.69
Previous Close€26.69
Volume0.00
Average Volume (3M)N/A
Market Cap
€7.62B
Enterprise Value€6.89B
Total Cash (Recent Filing)$1.00B
Total Debt (Recent Filing)$198.02M
Price to Earnings (P/E)―
Beta-0.09
Next Earnings
Oct 29, 2024EPS Estimate
€0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding285,251,725
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)3.57
Price to Sales (P/S)4.12
Price to Cash Flow (P/CF)17.30
P/FCF Ratio18.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.42
Enterprise Value/Gross Profit3.92
Enterprise Value/Ebitda15.10
Forecast
1Y Price Target
€27.63Price Target Upside3.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
Exelixis News
Bulls Say, Bears Say
Bulls Say
Business DevelopmentManagement continues to signal willingness for business development deals, particularly in the genitourinary sector.
Patent ProtectionEXEL's Cabometyx patent was upheld, granting market exclusivity until 2030.
Pipeline GrowthThe ruling allows EXEL to focus on generating more data for its next-gen TKI, zanza, in multiple Phase 3 studies.
Bears Say
Clinical TrialsThe CONTACT-02 trial's final overall survival analysis did not reach statistical significance.
Legal And IP IssuesIn the ANDA case between Exelixis and MSN Laboratories, the judge ruled that the Malate Salt Patents are not infringed.
Revenue GrowthThere is uncertainty regarding the ability of the company to replace and grow revenues through and beyond the 2030 cabozantinib patent cliff.
---
Options Prices
Currently, No data available
---
Ownership Overview
3.02% Insiders
22.74% Mutual Funds
0.91% Other Institutional Investors
47.61% Public Companies and
Individual Investors
EX9 FAQ
What was Exelixis’s price range in the past 12 months?
Exelixis lowest stock price was €17.84 and its highest was €26.69 in the past 12 months.
What is Exelixis’s market cap?
Currently, no data Available
When is Exelixis’s upcoming earnings report date?
Exelixis’s upcoming earnings report date is Oct 29, 2024 which is in 10 days.
How were Exelixis’s earnings last quarter?
Exelixis released its earnings results on Aug 06, 2024. The company reported €0.703 earnings per share for the quarter, beating the consensus estimate of €0.283 by €0.42.
Is Exelixis overvalued?
According to Wall Street analysts Exelixis’s price is currently Undervalued.
Does Exelixis pay dividends?
Exelixis does not currently pay dividends.
What is Exelixis’s EPS estimate?
Exelixis’s EPS estimate is €0.31.
How many shares outstanding does Exelixis have?
Exelixis has 285,251,740 shares outstanding.
What happened to Exelixis’s price movement after its last earnings report?
Exelixis reported an EPS of €0.703 in its last earnings report, beating expectations of €0.283. Following the earnings report the stock price went up 4.68%.
Which hedge fund is a major shareholder of Exelixis?
Among the largest hedge funds holding Exelixis’s share is Farallon Capital Management, L.L.C.. It holds Exelixis’s shares valued at 609M.
---
Exelixis Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€27.63 (3.53% Upside)
€27.63 (3.53% Upside)
Blogger Sentiment
Bullish
DE:EX9 Sentiment 94%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $5.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 80%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.36%
12-Months-Change
Fundamentals
Return on Equity
15.06%
Trailing 12-Months
Asset Growth
-11.75%
Trailing 12-Months
Company Description
Exelixis
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.
---
EX9 Company Deck
---
EX9 Earnings Call
Q2 2024
0:00 / 0:00
---
EX9 Revenue Breakdown
89.00% Net product revenues
9.76% License revenues
1.24% Collaboration services revenues
---
EX9 Stock 12 Month Forecast
Average Price Target
€27.63
▲(3.53% Upside)
Technical Analysis
Best Analysts Covering EX9
1 Year
1 Year Success Rate
15/15 ratings generated profit
1 Year Average Return
+23.91%
reiterated a buy rating 5 days ago
Copying Jason Gerberry's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +23.91% per trade.
---